Bipolar Disorder
Letter to the Editor: Bipolar I Disorder Exacerbation and COVID-19 Vaccination: Correspondence
Funding/financial disclosures. The authors have no conflict of interest relevant to the content of this letter. No funding was received for the preparation of this letter. Innov Clin Neurosci. 2023;20(1–3):8. Dear Editor: We would like to discuss the article, “Bipolar I Disorder Exacerbation Following COVID-19 Vaccination,”1 wherein Guina et al1 described the cases of a […]
Role of TNF-α -308G/A Polymorphism in Bipolar Disorder and its Relationship with Clinical and Demographic Variables
by Shama Akram, MPhil; Moazzam Ali, PhD; Zeeshan Mutahir, PhD; Nabeel Ibad, FCPS; Sana Sarmad, MPhil; Sumaira Mehboob, PhD; and Mahjabeen Saleem, PhD Ms. Akram and Drs. Ali and Mutahir are with School of Biochemistry and Biotechnology, University of the Punjab in Lahore, Pakistan. Dr. Ibad is with Shaikh Zayed Hospital in Lahore, Pakistan. Dr. Sarmad is […]
Bipolar I Disorder Exacerbation Following COVID-19 Vaccination
by Jeffrey Guina, MD; Sara Barlow, BS; and Duren Gutierrez, DNP Dr. Guina and Ms. Barlow are with Oakland University William Beaumont School of Medicine in Rochester, Michigan. Drs. Guina and Gutierrez are with Easterseals Michigan, Medical Services in Auburn Hills, Michigan. Dr. Guina is with Beaumont Health Psychiatry Residency, Graduate Medical Education in Southfield, […]
Capturing Clinical Symptoms with Ecological Momentary Assessment: Convergence of Momentary Reports of Psychotic and Mood Symptoms with Diagnoses and Standard Clinical Assessments
by Philip D. Harvey, PhD; Michelle L. Miller, MS; Raeanne C. Moore, PhD; Colin A. Depp, PhD; Emma M. Parrish, BS; and Amy E. Pinkham, PhD Dr. Harvey is with the University of Miami Miller School of Medicine in Miami, Florida, and Research Service at Bruce W. Carter VA Medical Center in Miami, Florida. Ms. […]
The Role of Serum Lithium Concentration on Pill Burden in Psychiatric Populations
by Charisse Chehovich, PharmD; Tammie Lee Demler, BS, PharmD, MBA, BCGP, BCPP; Emily Leppien, PharmD, BCPS; and Eileen Trigoboff, RN, PMHCNS-BC, DNS, DABFN Drs. Chehovich, Demler, and Trigoboff are affiliated with the Buffalo Psychiatric Center, New York State Office of Mental Health in Buffalo, New York and with the University at Buffalo School of Pharmacy […]
An Open-Label Prophylaxis Study of Lithium Plus Extended-Release Carbamazepine (ERC-CBZ) Combination for Rapid Cycling Bipolar Disorder
by Sriram Ramaswamy, MD; David Driscoll, PhD; and Lynette M. Smith, PhD Dr. Ramaswamy is with the Department of Psychiatry, Creighton University School of Medicine, Omaha, Nebraska, and the VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska. Dr. Driscoll is with the VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska. Dr. Smith is with the […]
MicroRNAs as Biomarkers for Psychiatric Conditions: A Review of Current Research
by Anoop Narahari, MD; Mariyah Hussain, MD; and Venkatesh Sreeram, MD Drs. Narahari, Hussain, and Sreeram are from the University of Alabama, Department of Psychiatry and Behavioral sciences, Birmingham, Alabama. Innov Clin Neurosci. 2017;14(1–2):53–55. Funding: No funding was received for the preparation of this article. Financial disclosures: The authors have no conflicts of interest relevant to […]
Cariprazine for Schizophrenia and Bipolar Disorder
by Jonathan R. Scarff, MD Dr. Scarff is a staff psychiatrist at the Veterans Affairs Outpatient Clinic in Spartanburg, South Carolina, USA Innov Clin Neurosci. 2016;13(9–10):49–52 Funding: The author has received no financial support for the writing of this manuscript. Financial Disclosures: The authors has no financial dislosures relevant to the content of this article. […]
Pharmaceutical Innovation in the Treatment of Schizophrenia and Mental Disorders Compared with Other Diseases
by Joanna P. MacEwan, PhD; Seth Seabury, PhD; Myrlene Sanon Aigbogun, MPH; Siddhesh Kamat, MS, MBA; Emma van Eijndhoven, MS, MA; Clement Francois, PhD; Crystal Henderson, PharmD, BCPP; and Leslie Citrome, MD, MPH Dr. MacEwan and Ms. van Eijndhoven are with Precision Health Economics in Los Angeles, California, USA; Dr. Seabury is with the University […]
Letter to the Editor: Gabapentin Abuse in a Patient with Comorbid Mood and Substance Use Disorders
Innov Clin Neurosci. 2016;13(7–8):13–14. Dear Editor: Substance use disorders frequently coexist with and complicate the treatment of mood and anxiety disorders. Gabapentin is one of the most commonly prescribed off-label medications in psychiatric settings.[1] Despite limited evidence, it has been used frequently in the treatment of mood and anxiety disorders in patients with comorbid substance […]
